Ophthalmology

Oraya Therapeutics Publishes Results of Wet AMD Treatment Study

Oraya Therapeutics, Newark, Calif.-based minimally invasive ophthalmic treatment company, has published the results of a study analyzing the effectiveness and safety of its wet age-related macular degeneration therapy in Ophthalmology.

Carrie Pallardy

Friday, April 19th, 2013

The INTREPID study demonstrated that Oraya Therapy Stereotactic Radiotherapy decreased the amount of anti-VEGF injections needed to treat macular degeneration patients.

More Articles on Ophthalmology:
3 Statistics on Cataract Surgery Procedure Times in ASCs
Abbott Medical Optics Appoints Dr. David Tanzer Chief Medical Officer
Hubble Telemedical Launches EyeQ Wellness Exam

Next Up in Ophthalmology

Prism adds Washington eye group to national network

Spokane (Wash.) Eye Clinic has joined Prism Vision Group’s network of affiliated practices. The affiliation expands Prism’s geographic reach beyond…

By: Sophie Eydis
Thursday, November 6th, 2025
Bascom Palmer Eye Institute to open 1st international facility

Bascom Palmer Eye Institute, part of UHealth – University of Miami Health System, is opening a facility in Abu Dhabi,…

By: Cameron Cortigiano
Thursday, October 30th, 2025
AmSurg acquires South Carolina ASC

Nashville, Tenn.-based AmSurg has acquired Surgery Center of Conway (S.C.), marking the organization’s fourth facility based in South Carolina. Surgery…

By: Cameron Cortigiano
Tuesday, October 28th, 2025

Comments are closed.

Inside the pharmacy overhaul that saved Texas Children’s millions

Next Up in Ophthalmology

Prism adds Washington eye group to national network

Bascom Palmer Eye Institute to open 1st international facility

AmSurg acquires South Carolina ASC

Join the 40,000+ ASC leaders who start their day with Becker's